Graves' dermopathy: Does octreotide scintigraphy predict the response to octreotide treatment?

Thyroid

Volumn 6, Issue 5, 1996, Pages 385-389

  Kuyvenhoven, Johan Ph ^a   Van Der Pijl, Johan W ^a   Goslings, Bernard M ^a   Wiersinga, Wilmar M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ADULT; ARTICLE; CASE REPORT; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GRAVES DISEASE; HUMAN; MALE; MYXEDEMA; PATIENT SELECTION; PRIORITY JOURNAL; SCINTISCANNING; SKIN DISEASE; TREATMENT OUTCOME;

EID: 0029908207     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1996.6.385     Document Type: Article

References (15)

1. Elte JWF, Hensen EJ 1983 Pretibial myxoedema. Report of 17 cases and review of the literature. Neth J Med 26:220-227.
2. Fatourechi V, Pajouhi M, Fransway AF 1994 Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine 74:1-7.
3. Chang TC, Kao SCS, Huang KM 1992 Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Br Med J 304:158.
4. Smith TJ, Bahn R, Gorman CA 1989 Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 10:366-391.
5. Peacy SR, Flemming L, Messenger A, Weetman AP 1996 Is Graves' dermopathy a generalized disorder? Thyroid 6:41-45.
6. Heufelder AE, Bahn RS, Scriba PC 1995 Analysis of T-cell receptor variable region gene usage in patients with thyroid-related pretibial dermopathy. J Invest Dermatol 105:372-378.
7. Lamberts SWJ, Krenning EP, Reubi J-C 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482.
8. Kriss JP 1987 Pathogenesis and treatment of pretibial myxoedema. Endocrinol Metab Clin North Am 16:409-415.
9. Tao T-W, Leu S-L, Kriss JP 1989 Biological activity of au-toantibodies associated with Graves' dermopathy. J Clin Endocrinol Metab 69:90-99.
10. Metcalfe RA, Davies R, Weetman AP 1993 Analysis of fibroblast-stimulating activity in IgG from patients with Graves' dermopathy. Thyroid 6:207-212.
11. Weetman AP 1993 Extrathyroidal complications of Graves' disease. Q J Med 86:473-477.
12. Priestley GC, Aldridge RD, Sime PJ, Wilson D 1994 Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin) in vitro. Br J Dermatol 131:52-56.
13. Tsuzaki S, Moses AC 1990 Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-1 in FRTL5 Cells. Endocrinology 126:3131-3138.
14. 1] octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity? J Clin Endocrinol Metab 79:1845-1851.
15. Krassas GE, Dumas A, Pontikides N, Kaltsas Th 1995 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 42:571-580.